BI/Lilly's Jardiance Enters US Heart Failure Market Fray

HFrEF Indication Approved

Boehringer Ingelheim and Eli Lilly have gained a US approval for their SGLT2 inhibitor empagliflozin in heart failure with reduced ejection fraction, which could be extended further in coming months to other types of heart failure, adding to the products competing in this previously neglected therapeutic area.

heart failure picture
• Source: Alamy

Two months after gaining the additional indication in the EU, Boehringer Ingelheim GmbH/Eli Lilly and Company’s Jardiance (empagliflozin) has been approved in the US for use in adult heart failure patients with reduced ejection fraction (HFrEF), where it will compete in a sector occupied by products such as AstraZeneca PLC’s Farxiga (dapagliflozin) and Novartis AG’s Entresto (sacubitril/valsartan).

And further details of empagliflozin’s potential benefits in a second group of heart failure patients, those with preserved ejection fraction...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip